pramlintide (symlin) Report issue

Biologics Peptide Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Pramlintide is an analog of human amylin. Amylin is co-secreted with insulin from pancreatic beta cells and acts centrally to slow gastric emptying, suppress postprandial glucagon secretion, and decrease food intake. These actions complement those of insulin to regulate blood glucose concentrations. Amylin is relatively deficient in patients with type 2 diabetes, depending on the severity of beta-cell secretory failure, and is essentially absent in patients with type 1 diabetes. Through mechanisms similar to those of amylin, pramlintide improves overall glycemic control, reduces postprandial glucose levels, and reduces bodyweight in patients with diabetes using mealtime insulin. SYMLIN® (pramlintide acetate) is indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.   NCATS

Chemistry

  • SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]5CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N5)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc8ccc(O)cc8)C(=O)N
  • InChIKey: TZIRZGBAFTZREM-MKAGXXMWSA-N
  • Mol. Mass: 3949.45
  • ALogP: Missing data
  • ChEMBL Molecules:
    pramlintide  
    pramlintide acetate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$339.8400 - $553.9800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ac0137 | ac 0137 | ac 137 | lys-cys-asn-thr-ala-thr-cys-ala-thr-gln-arg-leu-ala-asn-phe-leu-val-his-ser-ser-asn-asn-phe-gly-pro-ile-leu-pro-pro-thr-asn-val-gly-ser-asn-thr-tyr-nh2 | pramlintide | pramlintide acetate | symlin | symlinpen | tripro-amylin

Organizations (32)

Research & Development (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (1)


 

Diabetes Mellitus, Type 1 (approved 2005)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Alzheimer Disease (Early Phase 1)

Carcinoma, Squamous Cell (Early Phase 1)

Cognitive Dysfunction (Early Phase 1)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

General Surgery (Phase 4)

Hypoglycemia (Phase 4)

Obesity (Phase 2)

Overweight (Phase 2)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Weight Gain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial Organizations: 32

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue